At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
JKB-121: 5 mg twice daily +2 moredrug
Likely dose
JKB-121: 5 mg twice dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
In Brief
A Phase 2 clinical trial evaluating JKB-121: 5 mg twice daily, JKB-121: 10 mg twice daily, and 1 other intervention for Nonalcoholic Steatohepatitis. Completed, enrolled 65 participants across 8 sites.
Detailed Summary
To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in patients with biopsy-proven nonalcoholic steatohepatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartAug 2015
Primary CompletionSep 2017
TodayJul 2026
First PostedMay 13, 2015
Enrollment StartAug 1, 2015
Primary CompletionSep 24, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.1 years ago
Interventions
JKB-121: 5 mg twice dailydrug
JKB-121: 10 mg twice dailydrug
Placebodrug